IM-156 acetate, an activator of NADH dehydrogenase (IC50=2.2 μM) and AMP-activated protein kinase alpha (AMPKα), is an orally available and bioavailable inhibitor of mitochondrial oxidative phosphorylation (OxPhos).IM-156 acetate increases AMPKα activity and inhibits chlorhexadiene-induced peritoneal fibrosis and inhibit tumor growth in rats .

NADH dehydrogenase:2.2 µM, OCR:3.3 µM

IM-156 is an inhibitor of mitochondrial complex I, also known as an activator of NADH dehydrogenase (IC50 = 2.2 µM) and AMP-activated protein kinase α (AMPKα).[1][2]

It reduces the oxygen consumption rate (OCR; IC50 = 3.3 µM) and decreases mitochondrial ATP production in Eµ-Myc mouse lymphoma cells.1 IM-156 (10, 30, and 50 µM) increases AMPKα activity in primary rat peritoneal mesothelial cells and protects against chlorhexidine-induced peritoneal fibrosis in rats when administered at a dose of 1 mg/kg.2 It reduces tumor growth in an AT-84 murine oral cancer model and decreases age-related decline in novel object recognition, spatial working, and contextual memory in mice.[3][4]